EVOLVE104: A First-In-Category T-Cell Engager with Integrated CD2 Costimulation Targets ULBP2/5/6-Expressing Solid Tumors
Time: 4:45 pm
day: Day 1
Details:
- The integration of CD2 costimulation and carefully affinity-tuned CD3 binding mediate improved potency and superior efficacy of EVOLVE104 over conventional bispecific and clinical comparators
- The preclinical data demonstrate safety, efficacy, and developability of EVOLVE104, and support the upcoming Phase I clinical study
- ULBP2/5/6 is a novel target which is enriched on squamous cell tumors and transitional urothelial cancer, positioning EVOLVE104 to address underserved patient populations with high unmet needs
